Abstract 473P
Background
Surgical resection (R) ± adjuvant (adj) chemotherapy (CT) is recommended for patients (pts) with stage II–IIIA NSCLC and select pts with stage IB NSCLC, however, 5-yr overall survival rates are suboptimal. ADAURA showed a survival benefit with adj osimertinib after surgery ± adj CT in pts with resected stage IB–IIIA EGFR-mutation positive (EGFRm) NSCLC; this tx is now standard of care in this setting. EGFRm NSCLC is prevalent in China; we report the proportion of pts with EGFRm NSCLC, pt demographics and tx patterns from a Chinese cohort of a global retrospective rw study prior to adj osimertinib approval.
Methods
The study population included pts ≥18 yr old, with stage IA–IIIA NSCLC who had a test for EGFR mutations (EGFRmut) and were diagnosed 01 Jan 2015–31 Dec 2020. Primary objective assessed in these pts: proportion of EGFRm NSCLC. Pts diagnosed 01 Jan 2015–31 Dec 2017, who had complete surgical R, were assessed for pt characteristics and tx patterns (primary objectives) and sites of recurrence (secondary objective) from diagnosis until 31 Dec 2020 or last follow-up/death.
Results
Of 4,636 pts, 2,248 (48%) had EGFRm NSCLC, of whom 83% had common EGFRmut; proportion of common EGFRmut did not differ by age/NSCLC stage. Proportion of EGFRm NSCLC was similar in a subgroup of 300 pts who had R (149 [50%], 85% common EGFRmut). In pts who had R, mean age was 58 yr (range 31–81), 50% were female, 65% never smokers; open lobectomy (53%) and video-assisted thoracoscopic surgery (29%) were the most common first R procedures; 56% of pts did not receive systemic tx (Table). In pts who had R, 121 (40%) had recurrence, of whom 83% had distant recurrence; most common sites of recurrence: lung (45%), bone (17%), brain (13%) and pleura (10%). Table: 473P
Treatment received, n (%) | Patients who had resection n=300 | Disease stage | ||||
IA n=131 | IB n=60 | IIA n=28 | IIB n=18 | IIIA n=63 | ||
Surgery only | 169 (56) | 112 (85) | 29 (48) | 6 (21) | 6 (33) | 16 (25) |
Surgery + (neo)adjuvant treatment* | 131 (44) | 19 (15) | 31 (52) | 22 (79) | 12 (67) | 47 (75) |
Neoadjuvant treatment + surgery + adjuvant treatment | 4 (1) | 0 | 0 | 1 (4) | 0 | 3 (5) |
Surgery + adjuvant treatment | 127 (42) | 19 (15) | 31 (52) | 21 (75) | 12 (67) | 44 (70) |
*No patients received neoadjuvant treatment only
Conclusions
Around half of Chinese pts with stage IA–IIIA NSCLC in this study had EGFRm NSCLC. Of pts who had R, the majority did not receive systemic tx; these data highlight the need for early-stage EGFR testing to optimise tx choice.
Clinical trial identification
Editorial acknowledgement
Medical writing support for the development of this abstract, under the direction of the authors, was provided by Alice Walter, BSc, of Ashfield MedComms, an Inizio company, and was funded by AstraZeneca in accordance with Good Publications Practice (GPP) guidelines (http://www.ismpp.org/gpp-2022).
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
H. Wang: Non-Financial Interests, Personal, Local PI: AstraZeneca. S. Lu: Financial Interests, Personal, Research Funding: AstraZeneca, Hutchison, BMS, Heng Rui, BeiGene, Roche, Hansoh, Lilly Suzhou Pharmaceutical Co.Ltd; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Roche, Hansoh; Financial Interests, Personal, Advisory Board: Hengrui Therapeutics; Financial Interests, Personal, Advisory Role: AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison MediPharma, ZaiLab, GenomiCare, Yuhan Corporation, Menarini, InventisBio Co. Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Simcere Zaiming Pharmaceutical Co., Ltd., Roche. Y. Li: Non-Financial Interests, Personal, Local PI: AstraZeneca. G. Hu: Non-Financial Interests, Personal, Local PI: AstraZeneca. Q. Wang: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. S. Tan: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. M. Sandelin: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. D. Kahangire: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
461P - A randomized controlled trial of yoga in locally advanced non-small cell lung cancer patients receiving chemoradiotherapy
Presenter: Indranil Khan
Session: Poster Display
Resources:
Abstract
462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective
Presenter: Ann Kuo
Session: Poster Display
Resources:
Abstract
463P - The use of antipsychotic for managing delirium in patients with cancer
Presenter: Natasya Reina
Session: Poster Display
Resources:
Abstract
464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Presenter: Min Xiao
Session: Poster Display
Resources:
Abstract
465P - Oncological care needs of people with mental illness: A single institution experience in Australia
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India
Presenter: Rajesh Patidar
Session: Poster Display
Resources:
Abstract
467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management
Presenter: Li He
Session: Poster Display
Resources:
Abstract
468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong
Presenter: Olivia L T Chan
Session: Poster Display
Resources:
Abstract
469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Presenter: Pei-Jye Voon
Session: Poster Display
Resources:
Abstract